ArticleCancers2019
Immune Heterogeneity Between Primary Tumors and Corresponding Metastatic Lesions and Response to Platinum Therapy in Primary Ovarian Cancer.
Article in Cancers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 22 citations in OpenAlex.
- Harnessing lipid-driven immunometabolic pathways in omental metastases to enhance immunotherapy in patients with ovarian cancer.Signal transduction and targeted therapy · 2026Article
- Activin levels correlate with lymphocytic infiltration in epithelial ovarian cancer.Cancer medicine · 2024Article
- Pre-treatment inflamed tumor immune microenvironment is associated with FOLFIRINOX response in pancreatic cancer.Frontiers in oncology · 2023Article
- Review
- Development and Characterization of a Luciferase Labeled, Syngeneic Murine Model of Ovarian Cancer.Cancers · 2022Article
- Article
- Integration of local and systemic immunity in ovarian cancer: Implications for immunotherapy.Frontiers in immunology · 2022Review
- Personalized models of heterogeneous 3D epithelial tumor microenvironments: Ovarian cancer as a model.Acta biomaterialia · 2021Review
- Article
- The role of tumor heterogeneity in immune-tumor interactions.Cancer metastasis reviews · 2021Review
- PD-1 and PD-L1 expression on TILs in peritoneal metastases compared to ovarian tumor tissues and its associations with clinical outcome.Scientific reports · 2021Article
- Integrin α2β1 Represents a Prognostic and Predictive Biomarker in Primary Ovarian Cancer.Biomedicines · 2021Article
- Spatial and Temporal Heterogeneity of Tumor-Infiltrating Lymphocytes in Advanced Urothelial Cancer.Frontiers in immunology · 2021Article
- 4-1BB co-stimulation further enhances anti-PD-1-mediated reinvigoration of exhausted CD39Journal for immunotherapy of cancer · 2020Article
- Prognostic and Clinical Value of Interleukin 6 and CD45Journal of immunology research · 2020Article
- High expression of B7-H3 on stromal cells defines tumor and stromal compartments in epithelial ovarian cancer and is associated with limited immune activation.Journal for immunotherapy of cancer · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 6 institutions in 1 country.
Funding
Abstract
CD3
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.